SOUTH SAN FRANCISCO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that it will release results for the second quarter of 2005 after close of the stock market on Tuesday, November 2, 2005.
Company management will also host a conference call at 2:00 p.m. PST on November 2 to discuss third quarter 2005 results. The dial-in number for domestic callers will be 800-309-2906 and for international callers will be 706-634-0903. The conference ID number is 1901411.
To listen to the live webcast of the conference call please go to www.cotherix.com and click on the “Investor Relations” link. There will be a replay available for approximately two weeks following the call. The conference call, replay and webcast are open to all interested parties.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix’s Ventavis(R) (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in patients with New York Heart Association Class III or IV symptoms (World Health Organization Group I). PAH is a chronic, progressive and often fatal disease characterized by severe constriction of the blood vessels in the lungs that leads to very high pulmonary arterial pressure. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a registered trademark of Schering AG, Germany.
CoTherix, Inc.
CONTACT: Anne Bowdidge, Senior Director of Investor Relations of CoTherix,Inc., +1-650-808-6551
Web site: http://www.cotherix.com/
